The dual mechanism provides multiple pathways for weight reduction
BBS or POMC, PCSK1, or LEPR Deficiency The safety and effectiveness of IMCIVREE have been established to reduce excess body weight and maintain weight reduction long term in pediatric patients aged 2 years and older with obesity due to: BBS [see Clinical Studies (14.2, 14.4)] POMC, PCSK1, or LEPR deficiency with variants in POMC, PCSK1, or LEPRgenes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Clinical Studies (14.3, 14.4)] Use of IMCIVREE for these indications is supported by evidence from one 66-week trial, which included a 14-week, randomized, double-blind, placebo-controlled period followed by a 52-week open-label period, and included 22 pediatric patients with BBS aged 6 to 17 years (Trial 2)
2024 | 7:11AM (IST) Manufacturer details Survey no
doi:10.1089/acm.2010.0716 Rachel Erwin, Nutritionist & Content Writer Rachel is a Nutritionist with a BSc in Biology and Global Health from the University of Toronto, and a Postgraduate Diploma in Human Nutrition from the University of Ulster
GLP-1 medications can cause profound appetite suppression an effect that, for someone with restrictive eating, can reinforce dangerous patterns of food restriction, reduce food intake to medically dangerous levels, and provide what feels like medical sanction for not eating
While patients with large and giant CMN have the greatest overall lifetime risk of melanoma, estimated between 4.5 % and 10 % [5], all congenital nevi should be considered as potential precursor lesions and patients and parents should be educated to monitor for changes in appearance
